Scientific Online Resource System

Varna Medical Forum

Sociodemographic Characteristics Of Survival In Patients With Myelodysplastic Syndrome

Merlin Efraim, Ilina Micheva

Abstract

Myelodysplastic syndrome (MDS) is a heterogeneous group of acquired hematopoietic stem cell disоrders characterized by ineffective hematopoiesis and a high risk of transformation into acute myeloid leukemia (AML). Due to the phenotypic diversity of MDS, survival widely varies. The purpose of the present study is to analyze the impact of some socio-demographic characteristics on the survival of patients with MDS. We analyzed 219 patients with MDS, who were admitted in the Clinic of Hematology, University Hospital "St. Marina”- Varna for a period of 10 years (2010-2020). Survival was assessed by age, sex, FAB and WHO2016 subtype and risk group defined by IPSS, IPSS-R and WPSS. There is a significantly higher survival rate in women and an inversely proportional relationship between survival and age. Patients with RAEB and RAEB-t have the lowest survival as well as patients with high and very high risk. MDS presents with significant differences in survival between subtypes, age and sex. The outcome of the disease varies according to the risk group determined by the established scales for risk stratification, and the most accurate in the prognosis is IPSS-R.

Keywords

Myelodysplastic Syndrome, survival

Full Text


References

Kuendgen A, Strupp C, Aivado М еt al; Myelodysplastic syndromes in patients younger than age 50.J Clin Oncol. 2006 Dec 1; 24(34):5358-65

Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51::189,1982-199

Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002 Oct 1;100(7):2292-302.

Vardiman JW, Thiele J, Arber DA et al.. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51.

Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405.

Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89, 1997, 6, 2079-2088.9)

Greenberg PL, Tuechler H, Schanz J. et al ; Revised international prognostic scoring system for myelodysplastic syndromes.Blood. 2012 Sep 20; 120(12):2454-65.

Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 25, 2007, 23, 3503-3510

Ria R, Moschetta M, Reale A et al; Managing myelodysplastic symptoms in elderly patients. Clin Interv Aging. 2009; 4():413-23.

Malcovati L, Porta MG, Pascutto C et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005 Oct 20;23(30):7594-603.

Triantafyllidis I, Ciobanu A, Stanca O et al. Prognostic factors in myelodysplastic syndromes. Maedica (Bucur). 2012;7(4):295-302.

I Micheva, R Rachev, H Varbanov et al. Novel approaches in the classification and risk assessment of patients with myelodysplastic syndromes-clinical implication. Scripta Scientifica Medica, March 2014 DOI: 10.14748/ssm.v46i1.647




DOI: http://dx.doi.org/10.14748/vmf.v10i2.7970

Refbacks

User Guide

Font Size


|